---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066062"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-05-26T13:26:00+00:00"
generated_at: "2026-05-26T13:27:43.981584+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference

## Summary
- 16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.
- In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.
- At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.
- Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.
- Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints.

## SEC filing metadata
- accession: 0001104659-26-066062
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-05-26T13:26:00+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/0001104659-26-066062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926066062/tm2615594d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066062
- JSON: https://secwatch.observer/filing/0001104659-26-066062.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.